Israeli scientists say they will likely have a cure for cancer within a year, according to The Jerusalem Post.

Dan Aridor, CEO of Accelerated Evolution Biotechnologies Ltd., said his team is developing an anti-cancer drug that will target several mutations in cancer cells using a combination of several-cancer directed peptides. The treatment is called MuTaTo, or multiobjective toxin.

"Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market," Aridor said. "Our solution will be both generic and personal."

Cancer is an abnormal growth of cells. There are more than 100 types, including skin cancer, lung cancer, breast cancer and colon cancer, and the disease is the second leading cause of death in the United States.

More than half a million people died from cancer in 2015, a 1.7 percent decline from 2014.

Dr. Ilan Morad, who works with Aridor, is hopeful of Aebi's method.

"We make sure that the treatment is not affected by the mutations; the cancer cells can mutate in such a way that the cancer discards the targeted receptors."

"The probability of having multiple mutations that would modify all the targeted receptors decreases dramatically with the number of targets used," Morad continued. "Instead of attacking the receivers one at a time, we attack the receivers three at a time; even cancer cannot mutate three receptors at the same time."